Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured News from MarketBeat.com 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. However, if you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and do not have commercially available drugs or therapeutics. That also means negative earnings (they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. A new generation of AI is expected to come online in early 2026, and some analysts believe it could reshape multiple parts of the economy.
In a recent broadcast, one technology researcher explains why this shift may bring significant productivity gains and highlights a small group of lesser-known companies he believes are positioned to benefit as the transition unfolds. Watch the broadcast here Even if a product advances through trials, profitability can be years away; only then do companies usually attract the analyst coverage that draws institutional investment. Still, getting in on one of these medical stocks and seeing it succeed can produce outsized returns — 3x, 5x, or even 10x. Many will never pan out, which is why investors interested in penny stocks often spread capital across multiple biotech names. In a numbers game, diversification can be an effective way to manage risk. With that in mind, here are two small-cap biotech stocks that carry substantial risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike some penny stocks in the space, Mainz Biomed already has a commercially available product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced ColoAlert was added to the portfolio of DoctorBox, one of Germany’s leading digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the opportunity is material. Mainz Biomed is also developing a non-invasive blood-based screening test for early pancreatic cancer detection. The company reported positive topline results in October, but commercial approval is likely years away. That said, the risks are significant. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. The company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering, which for now helps keep the MYNZ stock price above $1 and avoids a delisting notice. Mainz Biomed is racing to generate enough revenue to move the needle. If it succeeds, however, even a modest investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral approach, but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces and lure viruses into binding with them, neutralizing the pathogens before they infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to keep programs moving. Recent filings indicate limited cash on hand, so investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For patient investors with a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
